Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 11

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 11
---
, thereby enhancing drug stability, bioavailability, and targeted delivery to diseased tissues such as tumors or infection
sites.

“Reticuloendothelial System (RES) represents
a network of immune cells, primarily in the liver, spleen, and lymph nodes, that filters pathogens and foreign particles from the blood,
often responsible for clearing nanoparticles and liposomal drugs.

“Spike protein” refers to the “spikes”
on the surface of the coronaviruses membranes that enables viral entry by binding a host receptor. They latch onto human or animal cells
(like a key fitting a lock) so the virus can get inside. Many COVID-19 vaccines train the immune system to recognize and block this spike.

“Tumor Microenvironment (TME)” are
the complex environment surrounding a tumor, including blood vessels, immune cells, fibroblasts, signaling molecules, and the extracellular
matrix, all of which influence tumor growth and drug response.

“VRE (Vancomycin-Resistant Enterococcus)”
refers to strains of Enterococcus bacteria that are resistant to vancomycin, an antibiotic often used as a last resort for treating
severe infections. VRE typically affects hospitalized patients, particularly those with weakened immune systems, and can lead to infections
in the urinary tract, bloodstream, or wounds.

<div align='center'>iv

PROSPECTUS SUMMARY</div>

This summary provides an overview of certain information contained elsewhere in this Prospectus and does not contain all of the information that you should consider or that may be important to you. Before making an investment decision, you should read the entire Prospectus carefully, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes thereto, in each case included in this Prospectus. Some of the statements in this Prospectus constitute forward-looking statements. See “Special Note About Forward-Looking Statements.” Except as otherwise indicated, referenced to the “Company,” “we,” “us” and “our” refer to Revium Rx., a Delaware corporation, prior to the reincorporation from Delaware to Nevada, and Revium, Rx., a Nevada corporation, following that reincorporation, and our wholly-owned subsidiaries, Revium RX Ltd.(formerly known as Revium Recovery Ltd.) and LipoVation Ltd. (“LipoVation”), which became our wholly-owned subsidiary on July 23, 2024.

Revium Rx is a
pre